Zobrazeno 1 - 4
of 4
pro vyhledávání: '"365"'
Autor:
G. F. Ferraccioli, R. Caporali, Alberto Cauli, Francesco Paolo Cantatore, Marco Sebastiani, Ennio Giulio Favalli, Giovanni Lapadula, Rosario Foti, Maurizio Rossini, Roberto Gorla, Carlomaurizio Montecucco, Florenzo Iannone, Fabrizio Conti, Elisa Gremese, Enrico Fusaro
Publikováno v:
Annals of the Rheumatic Diseases. 80:582.1-582
Background:Long-term observational data on the real-life use of JAK inhibitors (JAKis) for rheumatoid arthritis (RA) and their comparison with biological drugs are still very limited. Large population-based registries have been increasingly used to i
Autor:
Philip Brohawn, S. Yoo, M Khamashta, L. Wang, Kenneth C. Kalunian, Victoria P. Werth, Richard Furie, Joan T. Merrill, G. Illei, Jorn Drappa
Publikováno v:
Annals of the Rheumatic Diseases. 75:168.1-168
Background Increased activity of the type I interferon (IFN) pathway is central to the pathogenesis of SLE. Blocking the type I receptor may reduce SLE activity more effectively than inhibiting IFN-α alone. Objectives Efficacy and safety of anifrolu
Autor:
Giulio Cavalli, G. De Luca, Lorenzo Dagna, Nicola Farina, Alessandro Tomelleri, Elena Baldissera, Corrado Campochiaro
Publikováno v:
Annals of the Rheumatic Diseases. 80:955.3-956
Background:Adult-onset still’s disease (AOSD) is a rare systemic inflammatory disease. Interleukin-1 (IL1) blockade has shown to be crucial for the management of refractory AOSD patients. The IL1 inhibitors anakinra and canakinumab are both effecti
Autor:
Naoko Ishiguro, Toshihisa Kojima, S. Hirabara, Yuji Hirano, D. Kida, Atsushi Kaneko, Nobunori Takahashi
Publikováno v:
Annals of the Rheumatic Diseases. 74:455.1-455
Background Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often becomes problematic for RA treatment. Abatacept (ABT) has